On August 27, 2026 Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, reported that the first patient has been enrolled in the Phase 1b/2 BEXAR investigator-initiated trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BEXAR trial evaluates Faron’s lead asset, bexmarilimab, in combination with standard-of-care doxorubicin as a first-line treatment for patients with metastatic soft-tissue sarcoma.

The trial is sponsored by the international oncology research company MEDSIR and currently conducted at six hospitals across Spain, led by the Vall d’Hebron University Hospital in Barcelona. The Phase 1b/2 BEXAR trial is designed to evaluate the safety and tolerability of bexmarilimab in combination with doxorubicin in the Phase 1b stage, followed by a contingent randomized Phase 2 assessment of preliminary efficacy versus doxorubicin alone.

Dr. César Serrano, Group Leader of the Sarcoma Translational Research Program at the Vall d’Hebron Institute of Oncology and a member of the Sarcoma Faculty of the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper), and scientific and clinical lead of the trial said, "Metastatic soft-tissue sarcoma has seen limited therapeutic progress in decades, and remains particularly difficult to treat. By combining doxorubicin with bexmarilimab, we aim to test whether reprogramming immunosuppressive macrophages can help ignite an anti-tumor response and translate into clinical benefit."

This enrollment marks the first patient treated with bexmarilimab in the BEXAR trial and the first clinical evaluation of an anti-Clever-1 strategy in combination with doxorubicin in patients with soft-tissue sarcoma. Soft-tissue sarcomas are highly aggressive malignancies and many subtypes are characterized by an immunologically inactive tumor microenvironment heavily dominated by immunosuppressive macrophages. These tumors express some of the highest levels of Clever-1, the target receptor of bexmarilimab, providing a strong mechanistic rationale for this combination strategy.

Dr. Petri Bono, Chief Medical Officer at Faron, commented, "The initiation of patient enrollment in the BEXAR trial is a significant milestone for our solid tumor strategy. Sarcomas express exceptionally high levels of Clever-1, providing a strong biological rationale for investigating an anti-Clever-1 approach in this setting. By combining bexmarilimab with chemotherapy, this trial is the first opportunity to generate clinical evidence for bexmarilimab’s mechanism in soft-tissue sarcomas. If this combination shows evidence of synergy, it could support the rationale for exploring bexmarilimab with other chemotherapy backbones across Clever-1-expressing tumor types. We are proud to support the world-class team at Vall d’Hebron and look forward to the data this trial will generate."

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

(Press release, Faron Pharmaceuticals, AUG 27, 2026, View Source [SID1234670362])